🟢 NeoGenomics is trading 5.91% up in pre-market after raising 2026 revenue guidance

NeoGenomics is trading at $18.99, up 5.91%, in pre-market after reporting Q3 growth and raising 2026 guidance.

• October 28 results showed Q3 revenue of $209 million, up 11% year over year, while adjusted EBITDA rose 53%.
• 2026 revenue guidance increased to $807–809 million from $802–806 million; adjusted EBITDA guidance is about $60 million.
• The results and stronger outlook are the clearest company-specific explanation for the gain, despite broader technology-market weakness.